tocilizumab,rituximab
Roche,JW Pharma
[]
 for me with ild &amp; pah being the two primery causes of death in ssc i would consider both, but it also potentially puts the patient in a situation of decreasing quality of life from side effects (but of cause i am not a medical professional) is there a study on this i can read ?
From Germany. Views are my own.